| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANIE.201307387 |
| P8608 | Fatcat ID | release_4dncpa6xbncblerad3t6ydx5ae |
| P932 | PMC publication ID | 3914205 |
| P698 | PubMed publication ID | 24259466 |
| P5875 | ResearchGate publication ID | 258825191 |
| P50 | author | Nathanael Gray | Q28112823 |
| Matthew Meyerson | Q47451221 | ||
| John R. Engen | Q50420861 | ||
| Pasi A Jänne | Q74766165 | ||
| P2093 | author name string | John Hunter | |
| Jarrod A Marto | |||
| Kenneth D Westover | |||
| Ting Xie | |||
| Scott B Ficarro | |||
| Nam Doo Kim | |||
| Sang Min Lim | |||
| Taebo Sim | |||
| Hwan Geun Choi | |||
| Rane A Harrison | |||
| Michael E Pacold | |||
| Martin Carrasco | |||
| P2860 | cites work | Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling | Q24293500 |
| Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 | Q24309607 | ||
| Ras/Rap effector specificity determined by charge reversal | Q24315941 | ||
| The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants | Q24317051 | ||
| The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue | Q24323252 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas | Q24645081 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| Discovery of Potent and Selective Covalent Inhibitors of JNK | Q27676927 | ||
| Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins | Q27686798 | ||
| Mammalian Ras interacts directly with the serine/threonine kinase Raf | Q27860833 | ||
| The Guanine Nucleotide-Binding Switch in Three Dimensions | Q28131710 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase | Q28269621 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| ras genes | Q29547799 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| Hydrogen exchange mass spectrometry: what is it and what can it tell us? | Q33847013 | ||
| The importance of being K-Ras | Q34034093 | ||
| A structure-guided approach to creating covalent FGFR inhibitors | Q34061522 | ||
| Functional interrogation of the kinome using nucleotide acyl phosphates | Q34599227 | ||
| Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. | Q36221780 | ||
| Ras inhibition via direct Ras binding--is there a path forward? | Q38035669 | ||
| Therapeutic Strategies for Targeting Ras Proteins | Q39262217 | ||
| The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins | Q39426327 | ||
| A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival | Q39845869 | ||
| Controlling cell chemistry with caged compounds | Q40893629 | ||
| Prodrugs of phosphates and phosphonates | Q46137915 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 199-204 | |
| P577 | publication date | 2013-11-20 | |
| P1433 | published in | Angewandte Chemie International Edition | Q62023953 |
| P1476 | title | Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor | |
| P478 | volume | 53 |
| Q35878817 | 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. |
| Q54989340 | A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology |
| Q51179388 | A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2. |
| Q28547072 | A Pan-GTPase Inhibitor as a Molecular Probe |
| Q64277436 | A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer |
| Q28115305 | ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma |
| Q38329647 | Addressing the right targets in oncology: challenges and alternative approaches |
| Q36012325 | Allosteric inhibition of antiapoptotic MCL-1. |
| Q97532176 | Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence |
| Q55280438 | An anionic phthalocyanine decreases NRAS expression by breaking down its RNA G-quadruplex. |
| Q33701979 | Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration. |
| Q90307720 | Bifunctional Small-Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins |
| Q89226634 | Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor |
| Q40989800 | Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. |
| Q92219202 | Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene |
| Q38612789 | Computational allosteric ligand binding site identification on Ras proteins. |
| Q51180158 | Covalent Guanosine Mimetic Inhibitors of G12C KRAS. |
| Q91995280 | Covalent Inhibition in Drug Discovery |
| Q60193666 | Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells. |
| Q35858612 | Covalent targeting of acquired cysteines in cancer |
| Q38534932 | Current status of the development of Ras inhibitors |
| Q92453129 | Cysteine-based regulation of redox-sensitive Ras small GTPases |
| Q38837319 | Defeat mutant KRAS with synthetic lethality |
| Q47219538 | Design of small molecules that compete with nucleotide binding to an engineered oncogenic KRAS allele. |
| Q51347239 | Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site |
| Q48198158 | Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling. |
| Q38608107 | Direct Modulation of Small GTPase Activity and Function |
| Q34271187 | Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library |
| Q49721819 | Direct inhibition of RAS: Quest for the Holy Grail? |
| Q35089991 | Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q35863269 | Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides |
| Q38891257 | Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view |
| Q35163434 | Drugging the undruggable RAS: Mission possible? |
| Q46901200 | Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. |
| Q46715840 | Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. |
| Q92258798 | Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers |
| Q90357653 | From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers |
| Q35808124 | Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. |
| Q50154920 | Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis |
| Q38218298 | Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy |
| Q89922274 | Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring |
| Q37113976 | How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization |
| Q36341628 | Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies |
| Q27684047 | In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C |
| Q37540897 | Inhibition of RAS function through targeting an allosteric regulatory site. |
| Q35624144 | Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides |
| Q36338169 | Inhibition of prenylated KRAS in a lipid environment |
| Q31142381 | Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions |
| Q92100763 | Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry |
| Q26766684 | K-Ras protein as a drug target |
| Q37261936 | KRAS - An Evolving Cancer Target |
| Q49668169 | KRAS Alleles: The Devil Is in the Detail |
| Q89516473 | KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? |
| Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
| Q27007866 | KRAS as a Therapeutic Target |
| Q47563012 | KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer |
| Q89303329 | Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine |
| Q48217385 | Microsecond Timescale Dynamics of GDP-Bound Ras Underlies the Formation of Novel Inhibitor-Binding Pockets |
| Q38641385 | Modeling of RAS complexes supports roles in cancer for less studied partners |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q35213124 | Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer |
| Q90706520 | New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness |
| Q38233321 | Non-small-cell lung cancers: a heterogeneous set of diseases |
| Q42198469 | Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity |
| Q92602636 | Oncogenic G12D mutation alters local conformations and dynamics of K-Ras |
| Q99558636 | Overcoming Resistance to Drugs Targeting KRASG12C Mutation |
| Q47223139 | Posttranslational Modifications of RAS Proteins. |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q27005712 | Prodrugs of phosphonates and phosphates: crossing the membrane barrier |
| Q28829116 | Proteome-wide covalent ligand discovery in native biological systems |
| Q55384002 | Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. |
| Q52678686 | Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. |
| Q46107918 | Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States |
| Q30244673 | Rationale for RAS mutation-tailored therapies. |
| Q48246978 | Recent advances in the biology and therapy of medullary thyroid carcinoma. |
| Q42872239 | Replication in bioanalytical studies with HDX MS: aim as high as possible |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
| Q37038604 | Searching for the Chokehold of NRAS Mutant Melanoma. |
| Q27702605 | Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine |
| Q92063627 | Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression |
| Q47271754 | Small change, big effect: taking RAS by the tail through suppression of post-prenylation carboxylmethylation |
| Q35188280 | Small-molecule modulation of Ras signaling |
| Q54137051 | Sphingomyelin metabolism is a regulator of KRAS function |
| Q50355595 | Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer |
| Q35610049 | Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. |
| Q47129648 | Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching |
| Q39166555 | Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine |
| Q42353910 | Structure, signaling and the drug discovery of the Ras oncogene protein. |
| Q93104452 | Targeted Quantitative Profiling of GTP-Binding Proteins in Cancer Cells Using Isotope-Coded GTP Probes |
| Q30390894 | Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery |
| Q48907560 | Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. |
| Q30597330 | Targeting pathways downstream of KRAS in lung adenocarcinoma |
| Q33566753 | The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study |
| Q47643586 | The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants |
| Q39071250 | The RAS-Effector Interaction as a Drug Target |
| Q44441472 | The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential |
| Q26747403 | The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers |
| Q37122874 | Therapeutic Approaches to RAS Mutation |
| Q48225794 | Total Chemical Synthesis and Folding of All-l and All-d Variants of Oncogenic KRas(G12V). |
| Q34438500 | Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R |
| Q52753134 | mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors |
Search more.